Expert Q&A: Labs Must Take a Greater Role in Guiding Clinicians About Abnormal Data
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
It’s beginning to look like Illumina’s roll of the dice is going to come up snake eyes regarding the potential acquisition.
The way the No Surprises Act is implemented would essentially allow private health plans to set out-of-network rates in billing disputes.
Meant to be temporary, remote regulatory assessments proved so successful that the agency will not only continue, but expand their use.
In this month’s Labs in Court roundup, BioReference pays big to settle kickback allegations, among several other kickback-related cases.
With the final rule on PT published July 11, here are the five things lab managers need to know to keep their labs compliant.
D.C. Circuit Court of Appeals agrees with lab industry that CMS got Medicare lab pricing all wrong, but says it’s unable to intervene.
The OIG’s new Fraud Alert can help labs and other providers steer clear of potentially suspect arrangements with telemedicine companies.
Loss of constitutional abortion rights undermines privacy protection of patients seeking reproductive care.
Use of these codes has frequently raised concerns for compliance due to a lack of clarity regarding when they’re appropriate.
The new report could be a turning point in the battle to curb payor abuse of preauthorization requirements.